XLON
CIZ
Market cap9mUSD
May 23, Last price
1.85GBP
1D
12.12%
1Q
0.00%
IPO
-80.27%
Name
Cizzle Biotechnology Holdings PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.02%
Rev. gr., 5y
-55.19%
Revenues
0k
Net income
-2k
L-99.81%
CFO
-639k
L-26.72%
Profile
Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 1 | 661 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1) | (661) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (46) | (51) | |||||||
Tax Rate | |||||||||
NOPAT | 45 | (610) | |||||||
Net income | (2) -99.81% | (912) -76.74% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 305 | 595 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 41 | ||||||||
Net debt | (1,557) | (478) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (639) | (872) | |||||||
CAPEX | |||||||||
Cash from investing activities | (120) | ||||||||
Cash from financing activities | 305 | 595 | |||||||
FCF | 127 | (692) | |||||||
| Balance | |||||||||
Cash | 1,557 | 478 | |||||||
Long term investments | |||||||||
Excess cash | 1,557 | 478 | |||||||
Stockholders' equity | (4,366) | 4,277 | |||||||
Invested Capital | 5,873 | 2,154 | |||||||
ROIC | 1.12% | ||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 355,861 | 291,323 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (1) | (661) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||